New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed)

Archived

National Institutes of Health

Description

The purpose of this notice of funding opportunity (NOFO) is to stimulate the development of new treatments for genital herpes that suppress shedding and lesion formation and reduce transmission. This NOFO invites applications that propose research into a broad range of therapeutic approaches, including but not limited to development of new or improved antivirals, monoclonal antibodies, therapeutic vaccines, and gene editing technologies for treatment of patients living with genital herpes. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase is not guaranteed and will depend on the successful completion of milestones.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

NIH Grants Information<br/>grantsinfo@nih.gov
grantsinfo@nih.gov

Key dates & funding
  • PostedOct 15, 2024
  • ClosesJan 31, 2025
  • CFDA93.855
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro